现代肿瘤医学
現代腫瘤醫學
현대종류의학
Journal of Modern Oncology
2015年
21期
3151-3153
,共3页
丁友宏%闫坤%李志燕%刘风%严士光%李向阳
丁友宏%閆坤%李誌燕%劉風%嚴士光%李嚮暘
정우굉%염곤%리지연%류풍%엄사광%리향양
胃癌%新辅助化疗%手术
胃癌%新輔助化療%手術
위암%신보조화료%수술
gastric cancer%neoajuvant chemotherapy%surgical operation
目的:评估进展期胃癌患者新辅助化疗后再手术的临床疗效。方法:选择局部晚期胃癌患者44例分为两组:常规手术组和新辅助化疗+手术组,各22例,入院后行CT检查,新辅助化疗+手术组患者进行2个周期的新辅助化疗,再行CT复查,对比后进行手术治疗。结果:常规手术组肿瘤切除率为81.8%(18/22),获得根治性切除率为45.5%(10/22),剖腹探查率为18.2%(4/22);新辅助化疗+手术组肿瘤切除率为90.9%(20/22),获得根治性切除率为72.7%(16/22),剖腹探查率为9.1%(2/22)。两组均无手术死亡病例,并发症发生率差异无显著性。结论:进展期胃癌患者在新辅助化疗后,再进行手术治疗,可以提高手术根治率和切除率。
目的:評估進展期胃癌患者新輔助化療後再手術的臨床療效。方法:選擇跼部晚期胃癌患者44例分為兩組:常規手術組和新輔助化療+手術組,各22例,入院後行CT檢查,新輔助化療+手術組患者進行2箇週期的新輔助化療,再行CT複查,對比後進行手術治療。結果:常規手術組腫瘤切除率為81.8%(18/22),穫得根治性切除率為45.5%(10/22),剖腹探查率為18.2%(4/22);新輔助化療+手術組腫瘤切除率為90.9%(20/22),穫得根治性切除率為72.7%(16/22),剖腹探查率為9.1%(2/22)。兩組均無手術死亡病例,併髮癥髮生率差異無顯著性。結論:進展期胃癌患者在新輔助化療後,再進行手術治療,可以提高手術根治率和切除率。
목적:평고진전기위암환자신보조화료후재수술적림상료효。방법:선택국부만기위암환자44례분위량조:상규수술조화신보조화료+수술조,각22례,입원후행CT검사,신보조화료+수술조환자진행2개주기적신보조화료,재행CT복사,대비후진행수술치료。결과:상규수술조종류절제솔위81.8%(18/22),획득근치성절제솔위45.5%(10/22),부복탐사솔위18.2%(4/22);신보조화료+수술조종류절제솔위90.9%(20/22),획득근치성절제솔위72.7%(16/22),부복탐사솔위9.1%(2/22)。량조균무수술사망병례,병발증발생솔차이무현저성。결론:진전기위암환자재신보조화료후,재진행수술치료,가이제고수술근치솔화절제솔。
Objective:To explore the efficacy of neoajuvant chemotherapy interms of resectablity for the patients with advanced gastric cancer. Methods:All 44 patients with advanced gastric cancer were randomly divided into rou-tine surgical operation group and neoajuvant chemotherapy+surgical operation group. The patients were examined by CT before surgery. The patients in neoajuvant chemotherapy+surgical operation group received two cycles of neoaju-vant chemotherapy,and then were evaluated by CT. Results:In routine surgical operation group,the overall resect-ability rate was 81. 8%(18/22),and the curative resection rate was 45. 5%(10/22),18. 2%(4/22)was laparotomy rate. In neoauvant chemotherapy+surgical operation group,the overall respectability rate was 90. 9%(20/22),and the curative resection rate was 72. 7%(16/22),only 9. 1%(2/22)was laparotomy rate. No mortality was observed. There were no significant difference between two groups of toxicities. Conclusion:The overall resectability rate and the curative resection rate are increased in patients with advanced gastric cancer after neoajuvant chemotherapy.